Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

2.341 -0.089 (-3.67%)
Streaming Delayed Price Updated: 3:40 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion
Via Investor Brand Network
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports Major Clinical and Corporate Milestones as Phase 3 Alzheimer’s Trial Advances Toward Completion
Via Investor Brand Network
Topics Intellectual Property
News headline image
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Completes Site Activation and Marks First Patient Completions in Pivotal Phase 3 Alzheimer’s Trial
Via Investor Brand Network
News headline image
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces $3.4 Million Registered Direct Offering
Via Investor Brand Network
News headline image
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $6 Million Registered Direct Offering
Via Investor Brand Network
News headline image
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Friday? ↗
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
The market is filled with gapping stocks in Friday's session. ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Annovis Announces $6 Million Registered Direct Offering of Common Stock
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports Biomarker Data Showing Buntanetap Reduces Inflammation and Strengthens Neuronal Health in Alzheimer’s Patients
Via Investor Brand Network
News headline image
Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Appoints Mark Guerin as Chief Financial Officer
Via Investor Brand Network
News headline image
Annovis Appoints Mark Guerin as Chief Financial Officer
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Alphabet To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
News headline image
Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Advances Phase 3 Alzheimer’s Trial, Strengthens IP Portfolio, Reports Q2 2025 Results
Via Investor Brand Network
News headline image
Annovis Bio Narrows Loss in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Annovis Bio (NYSE:ANVS) Reports Narrower Q2 2025 Loss, Advances Alzheimer's and Parkinson's Trials ↗
Annovis Bio (NYSE:ANVS) reported a narrower Q2 2025 loss of $0.32/share vs. $0.41 estimate, with $17.1M cash on hand. Progress in Phase 3 Alzheimer's trial and IP updates highlight clinical focus.... 
Via Chartmill
News headline image
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Secures Full Patent Coverage for New Crystalline Form of Buntanetap
Via Investor Brand Network
Topics Intellectual Property
News headline image
Annovis Completes Full Patent Transfer to Crystal Buntanetap
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Why Medpace Shares Are Trading Higher By 45%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present Alzheimer’s Advances at AAIC 2025 in Toronto
Via Investor Brand Network
News headline image
Annovis to Attend the AAIC 2025 with Four Poster Presentations
From Annovis Bio Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.